Actively Recruiting
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Led by Washington University School of Medicine · Updated on 2025-10-24
18
Participants Needed
1
Research Sites
418 weeks
Total Duration
On this page
Sponsors
W
Washington University School of Medicine
Lead Sponsor
E
Exelixis
Collaborating Sponsor
AI-Summary
What this Trial Is About
The investigators hypothesize that the combination of eribulin and zanzalintinib will be tolerable and lead to improved progression-free survival (PFS) as compared to eribulin alone based on historical data.
CONDITIONS
Official Title
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically proven diagnosis of unresectable or metastatic leiomyosarcoma or adipocytic sarcoma
- Progressed on at least 1 line of prior therapy and have received no more than 4 lines of prior therapy
- Measurable disease per RECIST 1.1
- At least 18 years of age
- ECOG performance status 64 1
- Adequate bone marrow and organ function within 14 days before first dose as defined by blood counts, liver and kidney tests, and coagulation parameters
- Recovery to baseline or 64 grade 1 from prior adverse events, except stable low-grade toxicities
- Agreement to use adequate contraception during study and for specified time after last dose
- Ability to understand and willingness to sign informed consent
You will not qualify if you...
- Pure well-differentiated liposarcoma or low grade leiomyosarcoma
- Prior or concurrent malignancy that could interfere with study assessments
- Prior treatment with zanzalintinib
- Receipt of any kinase inhibitor within 2 weeks before first dose
- Receipt of cytotoxic, biologic, or systemic anticancer therapy within 4 weeks before first dose
- Recent radiation therapy within 2 to 6 weeks before first dose depending on site
- Currently receiving other investigational agents
- Untreated brain metastases or symptomatic brain disease
- History of allergic reactions to study drugs
- Use of certain anticoagulants or antiplatelet agents not allowed
- Use of complementary medications to treat the disease within 2 weeks before first dose
- Uncontrolled or significant recent illness including serious cardiovascular, gastrointestinal, infectious, bleeding, or psychiatric conditions
- Major surgery within 8 weeks or minor surgery within 5 days before first dose
- QT interval >480 ms on ECG before first dose
- Pregnant or breastfeeding women
- Inability to swallow tablets or suspensions
- Other conditions that compromise safety or study completion per investigator judgment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110
Actively Recruiting
Research Team
M
Mia C Weiss, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here